published meta-analysis   sensitivity analysis   studies

convalescent plasma treatment in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsPLACID, 2020 1.04 [0.66; 1.63] 1.04[0.66; 1.63]PLACID, 202010%464NAnot evaluable death or transfer to ICUdetailed resultsPLACID, 2020 1.07 [0.73; 1.57] 1.07[0.73; 1.57]PLACID, 202010%464NAnot evaluable deathsdetailed resultsLibster, 2020 0.50 [0.09; 2.71] PLACID, 2020 1.04 [0.66; 1.63] 0.99[0.64; 1.53]Libster, 2020, PLACID, 202020%624seriousnot evaluable clinical deteriorationdetailed resultsLibster, 2020 0.52 [0.29; 0.94] PLACID, 2020 1.04 [0.54; 1.99] 0.72[0.37; 1.43]Libster, 2020, PLACID, 2020258%624moderatenot evaluable mechanical ventilationdetailed resultsPLACID, 2020 0.99 [0.54; 1.81] 0.99[0.54; 1.81]PLACID, 202010%451NAnot evaluable viral clearance by day 7detailed resultsPLACID, 2020 1.20 [1.00; 1.44] 1.20[1.00; 1.44]PLACID, 202010%342NAnot evaluable ICU admissiondetailed resultsLibster, 2020 0.33 [0.07; 1.58] 0.33[0.07; 1.58]Libster, 202010%160NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-03-28 14:12 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 538,957 - roots T: 290